India to Uzbekistan: Ofloxacin Export Trade Route

The India to Uzbekistan Ofloxacin corridor is one of India's established pharmaceutical export routes, with 365 shipments documented worth a combined $7.7M USD. The route is dominated by MACLEODS PHARMACEUTICALS LTD, which alone accounts for roughly 15% of all export value, reflecting the consolidated nature of India's ofloxacin manufacturing sector.

Across 81 active suppliers, the average shipment value stands at $21.1K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Sea freight dominates at 84% of all shipments, consistent with ofloxacin's non-urgent bulk-order profile.

Shipment activity peaks during October–December, with an average transit time of 27 days port-to-port. The route has recorded an annual growth rate of 29.3%, placing it at rank #15 among India's top ofloxacin export destinations globally.

On the import side, key buyers of Indian ofloxacin in Uzbekistan include FE ADVANCE PHARMACEUTICAL BUSINESS, AGIO HEALTHCARE INTERNATIONAL LLC, FE BARAKA DORI FARM, LLC and 110 others. FE ADVANCE PHARMACEUTICAL BUSINESS is the single largest importer with 24 shipments valued at $1.4M USD.

India's ofloxacin exports to Uzbekistan are driven primarily by a handful of large-scale manufacturers. MACLEODS PHARMACEUTICALS LTD with 17 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 81 active exporters signals a competitive but concentrated market — buyers in Uzbekistan benefit from supplier diversity while the top tier handles the majority of volume.

The top 3 suppliers — MACLEODS PHARMACEUTICALS LTD, AGIO PHARMACEUTICALS LIMITED, KUSUM HEALTHCARE PRIVATE LIMITED — together account for 30% of total trade value on this route. The average shipment value of $21.1K USD reflects a mix of bulk commercial orders and smaller specialty shipments.

Beyond the primary product category, shipments on this route include closely related formulations such as drugs and pharmaceuticals harmless medicines levofloxacin tablets 500 mg and levoril n-1(levofloxacin intravenous infusion 0.5%w/vea.100ml con.(levofloxacinhemih.usp eq.to lev.500mg w.f.inj.usp q148260nos, suggesting that buyers in Uzbekistan tend to consolidate orders across related product lines from the same Indian supplier.

On the buying side, FE ADVANCE PHARMACEUTICAL BUSINESS is the largest importer with 24 shipments worth $1.4M USD — representing 18% of all ofloxacin imports from India on this route. A total of 113 buyers are active on this corridor.